Antipsychotic therapy amongst Cytochrome P450 2D6 poor metabolizers in the clinical practice: A case report.

Authors:
Adriana Fortea
Adriana Fortea
Hospital Clinic de Barcelona
Giovanni Oriolo
Giovanni Oriolo
Clinical Institute of Neuroscience
Merce Brunet
Virginia Fortuna
Virginia Fortuna
Hospital Clínic. Barcelona
Barcelona | Spain
Eduard Parellada
Eduard Parellada
Barcelona Clinic Schizophrenia Unit (BCSU)

Actas Esp Psiquiatr 2017 09 1;45(5):248-55. Epub 2017 Sep 1.

Departamento de Psiquiatría y Psicología, Instituto de Neurociencias, Hospital Clínic. Barcelona, España Barcelona Clinic Schizophrenia Unit (BCSU), Instituto de Neurociencias, Hospital Clínic de Barcelona, Universidad de Barcelona. Barcelona, España Institut d’Investigacions Biomèdiques Agustí Pi i Sunyer (IDIBAPS). Barcelona, España Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM). Barcelona, España.

September 2017
9 Reads

Publication Analysis

Top Keywords

metabolizers clinical
4
poor metabolizers
4
clinical practice
4
practice case
4
case report
4
p450 2d6
4
2d6 poor
4
therapy cytochrome
4
antipsychotic therapy
4
cytochrome p450
4
case
1
cytochrome
1
report
1
practice
1
p450
1
poor
1
antipsychotic
1
metabolizers
1
clinical
1
2d6
1

Similar Publications

Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study.

Pharmacogenetics 2002 Apr;12(3):235-40

Department of Pharmacoepidemiology & Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, The Netherlands.

To study the association between polymorphism of the cytochrome P450 2D6 gene (CYP2D6) and the risk of antipsychotic-induced extrapyramidal syndromes, as measured by the use of antiparkinsonian medication. Data for this case-control study were obtained from a psychiatric hospital where newly admitted patients are routinely screened for several CYP2D6 mutant alleles. Cases were patients prescribed antiparkinsonian medication during oral antipsychotic drug treatment in the period September 1994 to August 2000. Read More

View Article
April 2002

Cytochrome P450 2D6 genotype and methadone steady-state concentrations.

J Clin Psychopharmacol 2001 Apr;21(2):229-34

Département Universitaire de Psychiatrie Adulte, H pital de Cery, Prilly-Lausanne, Switzerland.

A genetic polymorphism of cytochrome P450 2D6 has been described with the existence of poor (zero functional genes), extensive (one or two functional genes), and ultrarapid metabolizers (three or more functional genes). The authors measured the steady-state trough (R)- (i.e. Read More

View Article
April 2001

The mephenytoin (cytochrome P450 2C 19) and dextromethorphan (cytochrome P450 2D6) polymorphisms in Saudi Arabians and Filipinos.

Pharmacogenetics 1995 Apr;5(2):64-71

Riyadh Armed Forces Hospital, Kingdom of Saudi Arabia.

Hitherto no estimate has been available of the genetic polymorphisms of S-mephenytoin hydroxylation in the Saudi Arabian or any other Middle Eastern population. A total of 102 healthy Saudi Arabian volunteer subjects were tested simultaneously with mephenytoin and dextromethorphan. Two poor metabolizers of S-mephenytoin and two poor metabolizers of dextromethorphan were found. Read More

View Article
April 1995

Cytochrome P450-2D6 Genotype Definition May Improve Therapy for Paroxysmal Atrial Fibrillation A Case of Syncope Following "Pill-in-the-Pocket" Quinidine plus Propafenone.

J Atr Fibrillation 2014 Feb-Mar;6(5):978. Epub 2014 Feb 28.

Department of Family Practice University of California Medical School at Davis Davis, California, USA.

Classes 1A, 1C and III anti-arrhythmics may be ineffective or induce adverse events including potentially fatal arrhythmias when administered in recommended doses. Serum levels of these medications vary widely during conventional dosing due in large part to variations in cytochrome P450-2D6 isoenzyme activity which metabolizes most antiarrhythmics in addition to over 25% of other commonly prescribed medications. 2D6 activity is also profoundly inhibited by some antiarrhythmics and other commonly used medications and varies widely between the individuals of all populations, a pattern which has resulted in separation of subjects into 4 phenotypes and genotypes consisting of poor metabolizers (PM), intermediate metabolizers (IM), efficient metabolizers (EM), and ultra-rapid metabolizers (UM). Read More

View Article
February 2014